Recently, we have shown that MK-886-an inhibitor of five lipoxygenase activating protein (FLAP) inhibits atherosclerosis in apolipoprotein E/LDL receptor-double knockout mice. We, therefore, wanted to find out if other FLAP inhibitor-BAYx1005 given at a dose of 1.88 mg per 100 mg of body weight per day during 16 weeks, could also attenuate atherogenesis. In apoE/LDLR-DKO mouse model BAYx1005 inhibited atherogenesis, measured both by" en face" method (23.84±2.7% vs. 15.16±1.4%) and" cross-section" method (497236±31516 µm2 vs. 278107±21824 µm2). This is the first report that shows the effect of BAYx1005 on atherogenesis in gene-targeted mice.